Night vision composition
AssigneeOcularis Pharma, LLC
InventorGerald Horn
Life of this patent
Estimating the term…
Abstract
A method for optimizing pupil size in individuals suffering from excessive pupillary dilation in dim light as well as through medication is disclosed. Alpha 1 antagonist is applied in an eye drop formulation to the eye, resulting in reduced pupil size in dim light, but less reduction in pupil size in bright light.
Claims18
An ophthalmic, night vision formulation, comprising:
- a sterile aqueous carrier;
- and
- a therapeutically effective amount of a pharmaceutically active compound characterized by its ability to contract a pupil of a human patient's eye so that the pupil is twice the size or less in dim light as compared to its size in bright light.
An ophthalmic formulation comprising:
- an aqueous solvent;
- and
- an alpha 1 antagonist.
An eyedropper, comprising:
- a hollow cylindrical barrel comprising a first end, a second end, and an inner surface;
- a means for providing suction to draw an aqueous formulation into the hollow cylinder barrel, the first end of the barrel configured to receive the means for providing suction to draw the formulation, the barrel having a small opening at the second end configured to permit passage of the formulation;
- wherein the formulation comprises an aqueous solvent and an alpha 1 antagonist.
A method, comprising:
- administering to an eye a formulation comprising an alpha 1 antagonist in an aqueous solution;
- and
- allowing the formulation to contract pupil diameter in dim light to a diameter twice or less pupil diameter in bright light.
A method for optimizing pupil diameter in dim light by minimizing its dilatation in response to less light, comprising administering a therapeutically effective amount of an alpha 1 antagonist to an eye of a person in need thereof.
A method of treatment, comprising:
- subjecting the eye of a human patient to refractive surgery;
- allowing the eye of the patient to recover;
- and
- administering to the patient a formulation comprised of an alpha 1 antagonist wherein the formulation is a liquid formulation applied directly to the eye of the patient.
Dependencies are inferred from the claim text.